Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1988-04-13
1989-08-29
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514418, A61K 3140
Patent
active
048617946
ABSTRACT:
This invention relates to the use of certain 3-substituted-2-oxindole-1-carboxamides of the formula ##STR1## and the pharmaceutically-acceptable base salts thereof wherein X is H, Cl or F; Y is H or Cl; and R is benzyl or thienyl to inhibit interleukin-1 biosynthesis in a mammal. This invention also relates to the use of such compounds for treating interleukin-1 mediated disorders and dysfunctions such as bone and connective tissue metabolism disorders and immune dysfunction in a mammal. The methods of this invention comprise administering an interleukin-1 biosynthesis inhibiting amount of the compounds and salts of this invention to such a mammal.
REFERENCES:
patent: 4556672 (1985-12-01), Kadin
patent: 4569942 (1986-02-01), Kadin
patent: 4677132 (1987-06-01), Hayward
patent: 4678802 (1987-07-01), Kadin
patent: 4725616 (1988-02-01), Kadin
Hayward, M., et al., "Mechanisms of Bone Loss: Rheumatoid Arthritis, Periodontal Disease and Osteoporosis", Agents and Actions, 22, 251-254 (1987).
Hayward, M., et al., Annual Reports in Medicinal Chemistry, 22, Sect. IV, Chapter 17, pp. 172-177 (1987).
Dinarello, C. A., "An Update on Human Interleukin-1: From Molecular Biology to Clinical Relevance", J. Clin. Immunol., 5, 285-297 (1985).
Camp, R.D. et al., "Psoriatic Skin Lesions Contain Biologically Active Amounts of an Interleukin 1-Like Compound", J. Immunol., 137, 3469-3474 (1986).
Dinarello, C. A., "Biology of Interleukin 1", FASEB J., 2, 108-115 (1988).
Dinarello, C. A., et al., "The Influence of Lipoxygenase Inhibitors on the In Vitro Production of Human Leukocytic Pyrogen and Lymphocyte Activating Factor (Interleukin-1)", Int. J. Immunopharmac., 6, 43-50 (1984).
Dinarello, C. A. et al., "Role of Arachidonate Metabolism in the Immunoregulatory Function of Human Leukocytic Pyrogen/Lymphocyte-Activating Factor/Interleukin 1", Immunol., 130, 890-895 (1983).
Pages 6-8 of the Presentation by Barry M. Bloom to Analysts of First Boston, New York City, New York on Sep. 10, 1987.
F-D-C Reports, Sep. 28, 1987, p. 11.
"Three Pfizer Drugs Promising; FDA Okay to be Sought in '89", Chemical Marketing Reporter, Sep. 14, 1987, p. 7.
F-D-C Reports, Sep. 14, 1987, p. 2.
Kunkel, S. L. et al., "Arachidontic Acid Metabolites Regulate Interleukin-1 Production," Biochemical and Biophysical Res. Copmm., 128:892-897 (1985).
Smith, R. J. et al., "Human Neutrophil Activation with Interleukin-1," Biochemical Pharmacology, 36:3851-3858 (1987).
Benson Gregg C.
Gobrogge Roger
Lumb J. Trevor
Pfizer Inc.
Richardson Peter C.
LandOfFree
3-substituted-2-oxindole-1-carboxamides as inhibitors of interle does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-substituted-2-oxindole-1-carboxamides as inhibitors of interle, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-substituted-2-oxindole-1-carboxamides as inhibitors of interle will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2238608